{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:38:56Z","timestamp":1761647936958},"reference-count":28,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T00:00:00Z","timestamp":1334188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The new oral anticoagulants may prove to be one of most significant innovations in clinical practice in the past 60 years. Apixaban and rivaroxaban are direct inhibitors of Factor Xa, while dabigatran inhibits Factor IIa. The predictable pharmacological profile of these new agents allows physicians to prescribe these drugs without the need for routine coagulation monitoring, which is the mainstay of warfarin therapy. In addition, these new agents have not been shown to have any food interactions and minimal drug\u2013drug interactions, interactions are limited to the p\u2010glycoprotein (p\u2010Gp) transporter or cytochrome P450 (CYP450) system, each drug is unique in its drug interaction profile, as will be discussed below. These unique pharmacokinetics profiles may usher in for clinicians a new era of managing thromboembolic disorders. In this article, the pharmacology of these new oral anticoagulants will be reviewed along with the major clinical trials evaluating the use of these agents for thromboembolic prophylaxis in patients undergoing total hip and knee arthroplastic surgery, the treatment of venous thromboembolic disorders and stroke prevention in atrial fibrillation. Am. J. Hematol., 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23208","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T14:02:48Z","timestamp":1332252168000},"source":"Crossref","is-referenced-by-count":11,"title":["Implementing the new oral anticoagulants into the hospital formulary"],"prefix":"10.1002","volume":"87","author":[{"given":"Michael","family":"Palladino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Swift,","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geno J.","family":"Merli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,12]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023143"},{"key":"e_1_2_10_3_2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1160\/TH08-07-0486","article-title":"Apixaban, an oral direct factor Xa inhibitor, inhibits human clot\u2010bound factor Xa activity in vitro","volume":"101","author":"Jiang X","year":"2009","journal-title":"Thromb Haemost"},{"issue":"2","key":"e_1_2_10_4_2","first-page":"p\u2010T","article-title":"Inhibition of measured thrombin generation in human plasma by Apixaban: A predictive mathematical model based on experimentally determined rate constants","volume":"5","author":"Luettgen JM","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_10_5_2","first-page":"P\u2013M","article-title":"Apixaban, an oral direct factor Xa inhibitor: Multiple\u2010dose safety, pharmacokinetics and pharmacodynamics in healthy subjects","volume":"5","author":"Frost C","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01166.x"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025569"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0659"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847010-00005"},{"key":"e_1_2_10_13_2","unstructured":"European Medicines Agency (EMEA). European public assessment report: Pradaxa. Available at:http:\/\/www\/emea.europa.eu\/humandocs\/PFFs\/EPAR\/pradaxa\/H\u2010829\u2010PI\u2010en.pdf accessed 14 January 2012."},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0758"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0667"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f2f264"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0328"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0591-8"},{"key":"e_1_2_10_26_2","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of direct thrombin inhibitor Dabigatran, by recombinant factor VIIa ore activated prothrombin complex concentrations","volume":"93","author":"van Ryn J","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080086"},{"key":"e_1_2_10_29_2","first-page":"277","article-title":"Incorporating clinical outcomes and economic consequences into drug formulary decisions: A practical approach","volume":"5","author":"Mather D","year":"1999","journal-title":"Am J Managed Care"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23208","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T17:39:18Z","timestamp":1697477958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,12]]},"references-count":28,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/ajh.23208"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23208","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,12]]}}}